D8440
15-脱氧-Δ12,14-前列腺素J2
≥95% (HPLC), 1 mg/mL in methyl acetate
别名:
11-氧化前列素-（5Z,9,12E,14E）-四烯-1-酸, 15-脱氧-Δ12,14-PGJ2
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H28O3
化学文摘社编号:
分子量:
316.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352211
EC Number:
201-185-2
MDL number:
产品名称
15-脱氧-Δ12,14-前列腺素J2, ≥95% (HPLC), 1 mg/mL in methyl acetate
InChI
1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6+,18-13+/t17-/m0/s1
InChI key
VHRUMKCAEVRUBK-GODQJPCRSA-N
SMILES string
CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O
assay
≥95% (HPLC)
form
liquid
concentration
1 mg/mL in methyl acetate
shipped in
wet ice
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
PPARγ（过氧化物酶体增殖物激活受体）的选择性激动剂。 抑制表达PPARγ和环氧合酶-2（COX-2）的癌细胞系的增殖。
15-脱氧-Δ12，14-前列腺素J2（15d-PGJ2）调节体内炎症反应。15d-PGJ2还引起核因子（NF）-κB依赖性转录的PPARγ依赖性抑制。它作为抗血管生成的因子，并触发内皮细胞凋亡。
Application
15-脱氧-Δ12，14-前列腺素J2已用于：
- 研究其对血管化脂肪组织模型中的脂质积累、活率/线粒体活性和脉管系统数量的效应
- 氧化物酶体增殖物激活受体（PPARγ）激动剂激活肠道脂肪酸结合蛋白（I-FABP）-PPARγ途径
- 作为培养培养基中的补充剂，用于诱导神经干细胞/祖细胞（NSPCs）分化
General description
15-脱氧-Δ12，14-前列腺素J2（15d-PGJ2）是前列腺素J2（PGJ2）的代谢产物，是前列腺素D2的天然衍生物。它是在炎症过程中产生的。
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2 - STOT SE 3
target_organs
Central nervous system
supp_hazards
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
15.8 °F - closed cup
flash_point_c
-9 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves
法规信息
危险化学品
此项目有
Min Zhao et al.
Oncotarget, 7(40), 64690-64701 (2016-09-08)
Accumulating evidence suggests that loss of the renal tubular epithelial phenotype plays an important role in the pathogenesis of renal tubulointerstitial fibrosis. Systemic activation of peroxisome proliferator-activated receptor γ (PPAR-γ) has been shown to be protective against renal fibrosis, although
M2 microglia promotes neurogenesis and oligodendrogenesis from neural stem/progenitor cells via the PPAR gamma signaling pathway
Yuan J, et al.
Oncotarget, 8(12), 19855-19855 (2017)
Divya Bafna et al.
International journal of molecular sciences, 21(12) (2020-06-18)
Breast cancer (BCa) is one of the most predominantly diagnosed cancers in women. Notably, 70% of BCa diagnoses are Estrogen Receptor α positive (ERα+) making it a critical therapeutic target. With that, the two subtypes of ER, ERα and ERβ
N-3 PUFAs attenuate ischemia/reperfusion induced intestinal barrier injury by activating I-FABP-PPAR$\gamma$ pathway
Wang X, et al.
Clinical Nutrition (Edinburgh, Scotland), 31(6), 951-957 (2012)
15-deoxy-Delta 12, 14-prostaglandin J2 a prostaglandin D2 metabolite generated during inflammatory processes
Shibata T, et al.
The Journal of biological chemistry, 277(12), 10459-10466 (2002)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持